Sini Z. Li

139 Renmin Middle Road
Changsha, 410011, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Public health intelligence-ready blueprint for strengthening community resilience: a multi-stakeholder qualitative study in tertiary Chinese hospitals.

Public health intelligence-ready blueprint for strengthening community resilience: a multi-stakeholder qualitative study in tertiary Chinese hospitals.

Journal: Frontiers in public health

Published: December 09, 2025

Reliability and Validity of the Chinese Version of the Parental Acceptance Questionnaire (6-PAQ) Among Parents of Children With or Without Hearing Loss.

Reliability and Validity of the Chinese Version of the Parental Acceptance Questionnaire (6-PAQ) Among Parents of Children With or Without Hearing Loss.

Journal: Journal of clinical psychology

Published: May 07, 2024

Risk factors and consequences of mental health problems in nurses: A scoping review of cohort studies.

Risk factors and consequences of mental health problems in nurses: A scoping review of cohort studies.

Journal: International journal of mental health nursing

Published: October 11, 2023

Cognitive-Based Interventions for Improving Psychological Health and Well-Being for Parents of Children with Developmental Disabilities: A Systematic Review and Meta-analysis.

Cognitive-Based Interventions for Improving Psychological Health and Well-Being for Parents of Children with Developmental Disabilities: A Systematic Review and Meta-analysis.

Journal: Journal of autism and developmental disorders

Published: July 06, 2023

Effectiveness of acceptance and commitment therapy-based interventions for improving the psychological health of parents of children with special health care needs: A systematic review and meta-analysis.

Effectiveness of acceptance and commitment therapy-based interventions for improving the psychological health of parents of children with special health care needs: A systematic review and meta-analysis.

Journal: Comprehensive psychiatry

Published: June 03, 2023

First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.

First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.

Journal: PloS one

Published: December 13, 2022

Comparative efficacy of various CHIs combined with western medicine for non-small cell lung cancer: A bayesian network meta-analysis of randomized controlled trials.

Comparative efficacy of various CHIs combined with western medicine for non-small cell lung cancer: A bayesian network meta-analysis of randomized controlled trials.

Journal: Frontiers in pharmacology

Published: September 06, 2022

Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study.

Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study.

Journal: Frontiers in public health

Published: May 28, 2022

Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study.

Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study.

Journal: PharmacoEconomics

Published: May 19, 2022

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer.

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer.

Journal: Frontiers in pharmacology

Published: December 09, 2021

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.

Journal: Frontiers in pharmacology

Published: September 17, 2021

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States.

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States.

Journal: Frontiers in pharmacology

Published: July 29, 2021

Showing 1-12 of 28

Last Updated: 09/26/2026